Viking Therapeutics, Inc. (NASDAQ: VKTX) Starts Presentation at 30th Annual ROTH Conference
Viking Therapeutics (NASDAQ: VKTX) is a clinical-stage biopharmaceutical company engaged in developing novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. Viking’s R&D activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. The company has global rights to a portfolio of five therapeutic programs in clinical trials or preclinical studies that are based on small molecules licensed from Ligand Pharmaceuticals Incorporated. For more information, visit the company’s website at www.vikingtherapeutics.com. About NetworkNewsWire NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via…







